Single and repeated testing of growth hormone secretory capacity in hypopituitarism using growth hormone releasing factor

1986 ◽  
Vol 113 (4_Suppl) ◽  
pp. S118-S122 ◽  
Author(s):  
O. BUTENANDT ◽  
M. EMMLINGER ◽  
H. DOERR
Keyword(s):  
Growth Hormone ◽  
Body Weight ◽  
Pituitary Gland ◽  
Bolus Injection ◽  
Hormone Deficiency ◽  
Test Results ◽  
Repeated Testing ◽  
Plasma Growth Hormone ◽  
Once Daily ◽  
Secretory Capacity

Abstract 38 patients with proven growth hormone deficiency (GHD) and 19 children with familial short stature received an iv GRF-bolus injection of 1 ug/kg body weight. Whereas in all control children plasma growth hormone rose significantly (mean of maximal values 36 ng/ml), only 7 out of 38 patients with GHD reached peak values of 8 ng/ml or more. GRF-priming by 1 ug GRF/kg BW given once daily s.c. for 5 days in 19 patients improved the response of the pituitary gland in 11. Thus, following the first GRF test, only 21 % of patients demonstrated function of the pituitary gland whereas 45 % did so when all test results are combined. To evaluate the pituitary function in patients with GHD correctly, GRF tests following a GRF priming period seems to be necessary to reactivate atrophic somatotropic cells of the pituitary gland.

Imitation of normal plasma growth hormone profile by subcutaneous administration of human growth hormone to growth hormone deficient children

1983 ◽  
Vol 102 (1) ◽  
pp. 6-10 ◽  
Author(s):  
J. Sandahl Christiansen ◽  
H. Ørskov ◽  
C. Binder ◽  
K. W. Kastrup
Keyword(s):  
Growth Hormone ◽  
Time Course ◽  
Subcutaneous Administration ◽  
Molecular Size ◽  
Hormone Deficiency ◽  
Gel Chromatography ◽  
Plasma Growth Hormone ◽  
Normal Children ◽  
Blood Samples ◽  
Long Term Treatment

Abstract. The time course of plasma growth hormone (hGH) levels following sc and im injection of hGH was studied in 12 children with growth hormone deficiency who had received long-term treatment with im injections of highly purified hGH. Also the spontaneous diurnal GH levels in 8 normal children of comparable age were recorded. Blood samples were obtained during 24 h after im and sc injections of 4 IU/m2 hGH and analysed for immunoreactive hGH. While a median peak value of 160 ng/ml (range 135 to 475 ng/ml) was obtained 2 h after im injection, sc injection resulted in a more sustained elevation reaching 41 ng/ml (range 32 to 51 ng/ml) at 6 h subsiding slowly with a median concentration of 15 ng/ml (range 5–24 ng/ml) persisting after 14 h. Gel chromatography demonstrated that the hGH immunoreactivity of blood samples obtained as late as 14 h after sc injection had unaltered molecular size. Seven of the patients were further studied after sc injection of 2 IU/m2 at 20.00 h instead of in the morning. A plasma profile was attained during the night which roughly approximated the average nocturnal plasma pattern of the normal children.

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse

2006 ◽  
Vol 291 (6) ◽  
pp. E1290-E1294 ◽  
Author(s):  
Maria Alba ◽  
Danilo Fintini ◽  
Alessia Sagazio ◽  
Betty Lawrence ◽  
Jean-Paul Castaigne ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Body Weight ◽  
Half Life ◽  
Subcutaneous Fat ◽  
Daily Administration ◽  
Good Growth ◽  
Duration Of Action ◽  
Once Daily ◽  
Releasing Hormone ◽  
Normal Body

Although the majority of children with isolated growth hormone (GH) deficiency have a good growth response to GH-releasing hormone (GHRH), the use of this therapeutic agent is limited by its very short half-life. Indeed, we have shown that, in mice with GHRH gene ablation (GHRH knockout; GHRHKO), even twice-daily injections of a GHRH analog are unable to normalize growth. CJC-1295 is a synthetic GHRH analog that selectively and covalently binds to endogenous albumin after injection, thereby extending its half-life and duration of action. We report the effects of CJC-1295 administration in GHRHKO animals. Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 μg of CJC-1295 at intervals of 24, 48, and 72 h. Placebo-treated GHRHKO mice and mice heterozygous for the GHRHKO allele served as controls. GHRHKO animals receiving daily doses of CJC-1295 exhibited normal body weight and length. Mice treated every 48 and 72 h reached higher body weight and length than placebo-treated animals, without full growth normalization. Femur and tibia length remained normal in animals treated every 24 and 48 h. Relative lean mass and subcutaneous fat mass were normal in all treated groups. CJC-1295 caused an increase in total pituitary RNA and GH mRNA, suggesting that proliferation of somatotroph cells had occurred, as confirmed by immunohistochemistry images. These findings demonstrate that treatment with once-daily administration of CJC-1295 is able to maintain normal body composition and growth in GHRHKO mice. The same dose is less effective when administered every 48 or 72 h.

Effect of chronic administration of insulin on pituitary gland content of growth hormone in the normal rat

1970 ◽  
Vol 48 (2) ◽  
pp. 85-89 ◽  
Author(s):  
Robert L. Hazelwood ◽  
John G. Galaznik
Keyword(s):  
Growth Hormone ◽  
Body Weight ◽  
Young Adult ◽  
Pituitary Gland ◽  
Chronic Administration ◽  
Female Rats ◽  
Pituitary Glands ◽  
Hypophysectomized Rats ◽  
Normal Rat ◽  
Gland Content

Acetone-dried pituitary glands from young adult female rats (starting weight 165–168 g) previously injected (s.c.) with doses of insulin of 0.5 U to 1.0 U/kg body weight for 4 days, and then with 2.0 U/kg 6 days a week for an additional 34 days, were bioassayed in young hypophysectomized rats for growth hormone content. Insulin-injected rats gained significantly more weight than saline-injected controls. The tibia cartilage width of the insulin-injected donor rats was greater than that of control rats after 9, 17, 24, and 31 days of insulin; pituitary gland preparations from these insulin-injected rats increased tibia cartilage widths slightly but significantly over those of rats injected with control pituitary gland preparations.

Genetic Anomalies of Growth Hormone Deficiency in Pediatrics

2020 ◽  
Vol 20 ◽  
Author(s):  
Majid Firouzi ◽  
Hamidreza Sherkatolabbasieh ◽  
Shiva Shafizadeh
Keyword(s):  
Growth Hormone ◽  
Pituitary Gland ◽  
Growth Hormone Deficiency ◽  
Early Treatment ◽  
Hormone Deficiency ◽  
Genetic Defects ◽  
Pituitary Hormone ◽  
Deficiency Disease ◽  
Complex Genetics ◽  
Future Consequences

: Several different proteins regulate, directly or indirectly, the production of growth hormone from the pituitary gland, thereby complex genetics is involved. Defects in these genes are related to growth hormone deficiency solely, or deficiency of other hormones, secreted from the pituitary gland including growth hormone. These studies can aid clinicians to trace the pattern of the disease between the families, start early treatment and predict possible future consequences. This paper highlights some of the most common and novel genetic anomalies concerning growth hormone, which are responsible for various genetic defects in isolated growth and combined pituitary hormone deficiency disease.

Hypertension and Cardiac Hypertrophy in Growth Hormone-Deficient Rats

1994 ◽  
Vol 87 (2) ◽  
pp. 239-243 ◽  
Author(s):  
Stephen B. Harrap ◽  
Shari R. Datodi ◽  
Emma K. Crapper ◽  
Leon A. Bach
Keyword(s):  
Blood Pressure ◽  
Growth Hormone ◽  
Body Weight ◽  
Cardiac Hypertrophy ◽  
Weight Ratio ◽  
The Body ◽  
Hormone Deficiency ◽  
Heart Weight ◽  
Deoxycorticosterone Acetate ◽  
F344 Rats

1. Growth hormone may influence cardiac growth during post-natal maturation or in response to hypertension, and the growth-hormone deficient dwarf rat model offers an opportunity to study this question. 2. We compared the blood pressure and heart weight of dwarf rats and Fischer (F344) control rats in early adulthood, after two hypertensive stimuli: unilateral renal ischaemia (two-kidney, one-clip) or the administration of deoxycorticosterone acetate and saline drinking fluid. 3. In untreated animals at 13 weeks of age the body weight of dwarf rats was significantly less than that of F344 rats, but the mean arterial pressure was similar. Although the hearts of dwarf rats were smaller than those of F344 rats, the heart weight/body weight ratio was significantly greater in dwarf rats. 4. Both dwarf and F344 rats developed similar hypertensive mean arterial pressures 5 weeks after left renal artery clipping or treatment with deoxycorticosterone acetate salt. The heart weights of hypertensive dwarf and F344 rats were equivalent, indicating a proportionally greater increase in cardiac size in dwarf rats for the same rise in blood pressure. 5. The plasma insulin-like growth factor-I level was markedly lower in dwarf than in F344 rats, and hypertension did not have any significant effects on these levels. 6. These findings indicate that the developmental increase in blood pressure and heart size in growing animals and the adaptive cardiac hypertrophy accompanying hypertension are not affected by growth hormone deficiency.

Plasma Growth Hormone Response to Synthetic GH-RH1-44 in 52 Children and Adults with Growth Hormone Deficiency of Various Etiologies

1985 ◽  
Vol 22 (1-2) ◽  
pp. 24-31 ◽  
Author(s):  
A. Pertzelan ◽  
R. Keret ◽  
B. Bauman ◽  
Z. Ben-Zeev ◽  
D.B. Olsen ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Growth Hormone Response ◽  
Hormone Deficiency ◽  
Hormone Response ◽  
Plasma Growth Hormone
Sign in / Sign up

Export Citation Format

Share Document